Mkts

UroGen Pharma Ltd.

NASDAQ: URGN
$34.49-0.66 (-1.88%)
As of Oct 23, 4:00 PM ET

Key statistics

Day range
33.8035.02
52-week range
16.5050.81
Today
Open34.44
Previous close34.49
Volume597.6K
Valuation
Market cap1.69B
P/E ratio—
EPS (TTM)-1.98
Income & risk
Dividend / yield—
Beta1.58
Avg volume863.3K
Discussion

URGN News

Stories mentioning URGN from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue50,95937,83727,48224,21520,25424,56525,20421,848
Cost of Goods Sold4,1393,2893,2783,5502,3302,4712,4532,229
Gross Profit46,82034,54824,20420,66517,92422,09422,75119,619
Operating Expenses
Research & Development15,59714,31414,00818,91419,87114,89411,35515,402
Sales General & Admin51,48639,34937,58243,19934,96734,85828,94130,056
Total Operating Expenses
Operating Income (Loss)(20,263)(19,115)(27,386)(41,448)(36,914)(27,658)(17,545)(25,839)
Interest Income931.00908.001,1761,6772,2042,8122,7571,534
Interest Expense
Other Expense
Pretax Income(28,346)(26,639)(34,401)(48,925)(43,451)(34,863)(23,582)(33,365)
Tax Provision(4,772)(275.00)(1,054)1,015392.002,64991.0038.00
Net Income (Loss)(23,574)(26,364)(33,347)(49,940)(43,843)(37,512)(23,673)(33,403)
Earnings Per Share (Basic)(0.47)(0.55)(0.69)(1.05)(0.92)(0.80)(0.51)(0.82)
Earnings Per Share (Diluted)
Weighted Average Shares Outstanding (Basic)50,18348,11648,05747,74047,42247,03146,78040,501
Weighted Average Shares Outstanding (Diluted)

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About URGN

UroGen Pharma Ltd. (NASDAQ: URGN) is a stock listed on the Nasdaq Stock Market under the ticker symbol URGN. It last traded at $34.49 (Oct 23, 2026, 4:00 PM ET), down 1.9% on the day. That gives UroGen Pharma a market capitalisation of $1.7B.

Over the past 52 weeks URGN has traded between $16.50 and $50.81.

Revenue for the quarter ended Mar 31, 2026 was $51.0M; a net loss of $23.6M. Revenue was up 152% from $20.3M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$51.0M-$23.6M-46.3%
Dec 31, 2025$37.8M-$26.4M-69.7%
Sep 30, 2025$27.5M-$33.3M-121.3%
Jun 30, 2025$24.2M-$49.9M-206.2%

From UroGen Pharma’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…